Page last updated: 2024-11-12

dalbavancin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID16134627
CHEMBL ID3301669
CHEBI ID82721
MeSH IDM0443425

Synonyms (32)

Synonym
ver-001
ristomycin a aglycone, 5,31-dichloro-38-de(methoxycarbonyl)-7-demethyl-19-deoxy-56-o-(2-deoxy-2-((10-methyl-1-oxoundecyl)amino)-beta-d-glucopyranuronosyl)-38-(((3-(dimethylamino)propyl)amino)carbonyl)-42-o-alpha-d-mannopyranosyl-n15-methyl-
ristomycin a aglycone, 5,31-dichloro-38-de(methoxycarbonyl)-7-demethyl-19-deoxy-56-o-(2-deoxy-2-((10-methyl-1-oxoundecyl)amino)-beta-d-glucopyranuronosyl)-38-(((3-(dimethylamino)propyl)amino)carbonyl)-42-o-alpha-d-mannopyranosyl-n(sup 15)-methyl-
bi397
mdl 64,397
bi 397
ver001
mdl-64397
b0u42518wl ,
dalbavancin [usan:inn:ban]
ver 001
808ui9ms5k ,
mdl 63,397
a-a-1
unii-808ui9ms5k
unii-b0u42518wl
vero001
CHEMBL3301669
dalbavancin b0
CHEBI:82721 ,
ristomycin a aglycone, 5,31-dichloro-38-de(methoxycarbonyl)-7-demethyl-19-deoxy-56-o-(2-deoxy-2-((10-methyl-1-oxoundecyl)amino)-.beta.-d-glucopyranuronosyl)-38-(((3-(dimethylamino)propyl)amino)carbonyl)-42-o-.alpha.-d-mannopyranosyl-n15-methyl-
KGPGQDLTDHGEGT-SZUNQUCBSA-N
Q5210237
HY-17586A
NCGC00420878-02
CS-0113796
j01xa04
dalbavancin (mart.)
dalbavancine
dtxcid10820716
dalbavancina
dalbavancinum

Research Excerpts

Overview

Dalbavancin is a lipoglycopeptide antibiotic with broad-spectrum activity against gram-positive cocci. It has a markedly prolonged serum elimination half-life.

ExcerptReferenceRelevance
"Dalbavancin is a lipoglycopeptide antibiotic with broad-spectrum activity against gram-positive cocci and a markedly prolonged serum elimination half-life. "( In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
Andes, D; Craig, WA, 2007
)
2.03

Pharmacokinetics

ExcerptReferenceRelevance
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Dosage Studied

ExcerptRelevanceReference
"Dalbavancin, a semisynthetic lipoglycopeptide being developed for the treatment of skin and skin structure infections (SSSIs), has a half-life of 5 to 7 days in humans and offers promise for a convenient weekly dosing regimen."( Bactericidal activity and resistance development profiling of dalbavancin.
Draghi, DC; Goldstein, BP; Hogan, P; Sahm, DF; Sheehan, DJ, 2007
)
2.02
"8 to 480 mg/kg/6 days fractionated into 2, 4, 6, or 12 doses over the 144-h dosing period."( In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
Andes, D; Craig, WA, 2007
)
0.59
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antibacterial drugA drug used to treat or prevent bacterial infections.
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
carbohydrate acid derivativeA carbohydrate derivative that is formally obtained from a carbohydrate acid.
monosaccharide derivativeA carbohydrate derivative that is formally obtained from a monosaccharide.
glycopeptideAny carbohydrate derivative that consists of glycan moieties covalently attached to the side chains of the amino acid residues that constitute the peptide.
semisynthetic derivativeAny organic molecular entity derived from a natural product by partial chemical synthesis.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (316)

Assay IDTitleYearJournalArticle
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID342916Drug level in New Zealand white rabbit periostium assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 120 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324061AUC/MIC ratio of Streptococcus pneumoniae 1325 infected neutropenic mouse thigh infection model at 1.46 mg/kg, ip administered every 24 hrs by static effect experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324112AUC/MIC ratio of Staphylococcus aureus Smith infected neutropenic mouse thigh infection model at 95 mg/kg, ip administered every 72 hrs by 1-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324080AUC/MIC ratio of Staphylococcus aureus 33591 infected neutropenic mouse thigh infection model at 74 mg/kg, ip administered every 72 hrs by static effect experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342714Drug level in New Zealand white rabbit blood assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 12 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324072AUC/MBC ratio of methicillin-resistant Staphylococcus aureus infected neutropenic mouse thigh infection model at 37.7 mg/kg, ip administered every 24 hrs by static effect experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID285232Antimicrobial activity against methicillin-resistant Staphylococcus aureus FB1051634 by broth microdilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activity and resistance development profiling of dalbavancin.
AID324114AUC/MIC ratio of Staphylococcus aureus 31005 infected neutropenic mouse thigh infection model at 94.6 mg/kg, ip administered every 72 hrs by 1-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID548738Antimicrobial activity against Oxacillin-resistant Staphylococcus aureus assessed as percent susceptible isolate by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.
AID324083AUC/MIC ratio of Staphylococcus aureus 307109 infected neutropenic mouse thigh infection model at 31 mg/kg, ip administered every 72 hrs by static effect experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID510801Antimicrobial activity against Bacillus anthracis str. Ames infected in BALB/c mouse prophylaxis model assessed as mouse survival at >=15 mg/kg, ip administered 24 hrs post infection every 36 hrs for 14 days measured after 42 days2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
AID342695Drug level in New Zealand white rabbit bone assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 72 hrs by liquid scintillation counting method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID342958Drug level in New Zealand white rabbit bone marrow assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 336 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324015Antibacterial activity against Streptococcus pneumoniae 1329 by microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324128AUC/MIC ratio of methicillin-resistant Staphylococcus aureus infected neutropenic mouse thigh infection model at 53.5 mg/kg, ip administered every 24 hrs by 2-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID548745Antimicrobial activity against Beta-hemolytic Streptococcus assessed as percent susceptible isolate by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.
AID342910Drug level in New Zealand white rabbit blood assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 120 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID342712Drug level in New Zealand white rabbit cerebrospinal fluid assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 12 hrs by liquid scintillation counting method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324021Antibacterial activity against Staphylococcus aureus Smith by microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324023Half life in bacterial pathogen-infected neutropenic Swiss ICR mouse thigh infection model at 2.5 mg/kg, ip2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324022Antibacterial activity against Staphylococcus aureus 307109 by microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324124AUC/MIC ratio of Streptococcus pneumoniae 1329 infected neutropenic mouse thigh infection model at 1.45 mg/kg, ip administered every 24 hrs by 2-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342707Drug level in New Zealand white rabbit nucleus pulposus assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 72 hrs by liquid scintillation counting method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID510800Ratio of fAUC in ICR mouse at 5 mg/kg, ip to MIC against Bacillus anthracis Ames2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
AID324027AUC in bacterial pathogen-infected neutropenic Swiss ICR mouse thigh infection model at 5 mg/kg, ip2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342963Drug level in New Zealand white rabbit skeletal muscle assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 168 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID342941Drug level in New Zealand white rabbit ligament assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 168 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID548740Antimicrobial activity against Oxacillin-resistant coagulase-negative Staphylococcus assessed as percent susceptible isolate by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.
AID510955Antimicrobial activity against Bacillus anthracis after 18-24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
AID324052Bactericidal activity against penicillin-susceptible Streptococcus pneumoniae ATCC 10813 infected neutropenic Swiss ICR mouse thigh infection model assessed as drug level causing 2-log reduction of bacterial count at 1.26 mg/kg, ip dosed every 36 hrs2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324086AUC/MBC ratio of Staphylococcus aureus 33591 infected neutropenic mouse thigh infection model at 74 mg/kg, ip administered every 72 hrs by static effect experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342913Drug level in New Zealand white rabbit periostium assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 12 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324103AUC/MBC ratio of Staphylococcus aureus Smith infected neutropenic mouse thigh infection model at 50.7 mg/kg, ip administered every 24 hrs by 1-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324097AUC/MIC ratio of Staphylococcus aureus 33591 infected neutropenic mouse thigh infection model at 27.7 mg/kg, ip administered every 24 hrs by 1-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342929Drug level in New Zealand white rabbit compact bone assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 168 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID342965Drug level in human urine assessed as hydroxydalbavancin level2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID342708Drug level in New Zealand white rabbit nucleus pulposus assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 120 hrs by liquid scintillation counting method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID285247Bacterial killing activity of methicillin-susceptible Staphylococcus aureus at 0.25 ug/ml2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activity and resistance development profiling of dalbavancin.
AID285245Antimicrobial activity against vancomycin-susceptible Enterococcus faecalis FB7693342007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activity and resistance development profiling of dalbavancin.
AID342944Drug level in New Zealand white rabbit synovial space assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 24 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324127AUC/MIC ratio of Staphylococcus aureus 33591 infected neutropenic mouse thigh infection model at 33.5 mg/kg, ip administered every 24 hrs by 2-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID510951Cmax in ICR mouse at 5 mg/kg, ip after 2 hrs2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
AID324013Antibacterial activity against Streptococcus pneumoniae 1293 by microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342937Drug level in New Zealand white rabbit ligament assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 12 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324093AUC/MIC ratio of Streptococcus pneumoniae 1325 infected neutropenic mouse thigh infection model at 1.6 mg/kg, ip administered every 24 hrs by 1-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID548531Antimicrobial activity against Vancomycin-susceptible Enterococcus faecium by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.
AID324065AUC/MIC ratio of Staphylococcus aureus 33591 infected neutropenic mouse thigh infection model at 22.3 mg/kg, ip administered every 24 hrs by static effect experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324062AUC/MIC ratio of Streptococcus pneumoniae 1329 infected neutropenic mouse thigh infection model at 0.90 mg/kg, ip administered every 24 hrs by static effect experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324138AUC/MIC ratio of Streptococcus pneumoniae ATCC 10813 infected neutropenic mouse thigh infection model at 0.82 mg/kg, ip administered every 72 hrs by 2-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID285230Antimicrobial activity against methicillin-susceptible Staphylococcus aureus FB892379 by broth microdilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activity and resistance development profiling of dalbavancin.
AID548530Antimicrobial activity against Vancomycin-nonsusceptible Enterococcus faecalis by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.
AID324012Antibacterial activity against Streptococcus pneumoniae 1199 by microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324025Cmax in bacterial pathogen-infected neutropenic Swiss ICR mouse thigh infection model at 2.5 mg/kg, ip2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342696Drug level in New Zealand white rabbit bone assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 120 hrs by liquid scintillation counting method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID285239Antimicrobial activity against Staphylococcus haemolyticus FB954177 by broth microdilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activity and resistance development profiling of dalbavancin.
AID510806AUC (0-infinity) in ICR mouse at 20 mg/kg, ip2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
AID510798Antimicrobial activity against Bacillus anthracis str. Ames infected in BALB/c mouse assessed as mouse survival at 30 mg/kg, ip bid administered 24 hrs post infection for 14 days measured after 42 days2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
AID285234Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus FB9886442007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activity and resistance development profiling of dalbavancin.
AID285233Antimicrobial activity against methicillin-resistant Staphylococcus aureus FB1065524 by broth microdilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activity and resistance development profiling of dalbavancin.
AID285244Antimicrobial activity against vancomycin-susceptible Enterococcus faecalis FB7667822007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activity and resistance development profiling of dalbavancin.
AID324014Antibacterial activity against Streptococcus pneumoniae 1325 by microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324088AUC/MBC ratio of Staphylococcus aureus Smith infected neutropenic mouse thigh infection model at 59 mg/kg, ip administered every 72 hrs by static effect experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324094AUC/MIC ratio of Streptococcus pneumoniae 1329 infected neutropenic mouse thigh infection model at 1.18 mg/kg, ip administered every 24 hrs by 1-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324113AUC/MIC ratio of Staphylococcus aureus 307109 infected neutropenic mouse thigh infection model at 34 mg/kg, ip administered every 72 hrs by 1-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324043Protein binding in Staphylococcus aureus infected neutropenic mouse serum2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342942Drug level in New Zealand white rabbit ligament assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 336 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324109AUC/MIC ratio of Staphylococcus aureus ATCC 25923 infected neutropenic mouse thigh infection model at 185 mg/kg, ip administered every 72 hrs by 1-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324145AUC/MBC ratio of Staphylococcus aureus ATCC 25923 infected neutropenic mouse thigh infection model at 214 mg/kg, ip administered every 72 hrs by 2-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324017Antibacterial activity against Staphylococcus aureus ATCC 25923 by microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324135AUC/MIC ratio of Streptococcus pneumoniae 1293 infected neutropenic mouse thigh infection model at 1.68 mg/kg, ip administered every 72 hrs by 2-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324106AUC/MIC ratio of Streptococcus pneumoniae 1199 infected neutropenic mouse thigh infection model at 0.85 mg/kg, ip administered every 72 hrs by 1-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324147AUC/MBC ratio of methicillin-resistant Staphylococcus aureus infected neutropenic mouse thigh infection model at 85 mg/kg, ip administered every 72 hrs by 2-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342692Plasma concentration in New Zealand white rabbit assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 336 hrs by liquid scintillation counting method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324038Half life in bacterial pathogen-infected neutropenic Swiss ICR mouse thigh infection model at 40 mg/kg, ip2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324048Bactericidal activity against penicillin-susceptible Streptococcus pneumoniae ATCC 10813 infected neutropenic Swiss ICR mouse thigh infection model assessed as drug level causing 1-log reduction of bacterial count at 1.34 mg/kg, ip dosed every 24 hrs2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342704Drug level in New Zealand white rabbit bone marrow assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 336 hrs by liquid scintillation counting method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID548741Antimicrobial activity against Vancomycin-susceptible Enterococcus faecalis assessed as percent susceptible isolate by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.
AID342919Drug level in New Zealand white rabbit articular cartilage assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 12 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324146AUC/MBC ratio of Staphylococcus aureus 33591 infected neutropenic mouse thigh infection model at 114 mg/kg, ip administered every 72 hrs by 2-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID510960fAUC in ICR mouse at 5 mg/kg, ip2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
AID324019Antibacterial activity against Staphylococcus aureus 31005 by microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID67342Antibacterial activity against Enterococcus species., VanA2003Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23
Semi-synthetic glycopeptide antibacterials.
AID324098AUC/MIC ratio of methicillin-resistant Staphylococcus aureus infected neutropenic mouse thigh infection model at 45.3 mg/kg, ip administered every 24 hrs by 1-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342964Drug level in New Zealand white rabbit skeletal muscle assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 336 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID548526Antimicrobial activity against Oxacillin-resistant Staphylococcus aureus by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.
AID324107AUC/MIC ratio of Streptococcus pneumoniae 1396 infected neutropenic mouse thigh infection model at 0.61 mg/kg, ip administered every 72 hrs by 1-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342926Drug level in New Zealand white rabbit compact bone assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 24 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324095AUC/MIC ratio of Streptococcus pneumoniae ATCC 10813 infected neutropenic mouse thigh infection model at 1.54 mg/kg, ip administered every 24 hrs by 1-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324030AUC in bacterial pathogen-infected neutropenic Swiss ICR mouse thigh infection model at 10 mg/kg, ip2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342693Drug level in New Zealand white rabbit bone assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 12 hrs by liquid scintillation counting method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID342930Drug level in New Zealand white rabbit compact bone assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 336 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID342710Drug level in New Zealand white rabbit nucleus pulposus assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 336 hrs by liquid scintillation counting method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324034Cmax in bacterial pathogen-infected neutropenic Swiss ICR mouse thigh infection model at 20 mg/kg, ip2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324108AUC/MIC ratio of Streptococcus pneumoniae ATCC 10813 infected neutropenic mouse thigh infection model at 0.77 mg/kg, ip administered every 72 hrs by 1-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342713Drug level in New Zealand white rabbit cerebrospinal fluid assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 24 hrs by liquid scintillation counting method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID548525Antimicrobial activity against Oxacillin-susceptible Staphylococcus aureus by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.
AID324087AUC/MBC ratio of methicillin-resistant Staphylococcus aureus infected neutropenic mouse thigh infection model at 43 mg/kg, ip administered every 72 hrs by static effect experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342952Drug level in New Zealand white rabbit meniscus assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 120 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324117AUC/MBC ratio of methicillin-resistant Staphylococcus aureus infected neutropenic mouse thigh infection model at 62 mg/kg, ip administered every 72 hrs by 1-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID510957Ratio of fAUC in ICR mouse at 20 mg/kg, ip to MIC against Bacillus anthracis Ames2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
AID342915Drug level in New Zealand white rabbit periostium assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 72 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID548534Antimicrobial activity against viridans group Streptococcus by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.
AID324131AUC/MBC ratio of Staphylococcus aureus 33591 infected neutropenic mouse thigh infection model at 33.5 mg/kg, ip administered every 24 hrs by 2-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID548532Antimicrobial activity against Vancomycin-nonsusceptible Enterococcus faecium by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.
AID548529Antimicrobial activity against Vancomycin-susceptible Enterococcus faecalis by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID548528Antimicrobial activity against Oxacillin-resistant coagulase-negative Staphylococcus by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.
AID510803Ratio of fCmax in ICR mouse at 5 mg/kg, ip after 2 hrs to MIC for Bacillus anthracis Ames2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
AID324081AUC/MIC ratio of methicillin-resistant Staphylococcus aureus infected neutropenic mouse thigh infection model at 43 mg/kg, ip administered every 72 hrs by static effect experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324133AUC/MBC ratio of Staphylococcus aureus Smith infected neutropenic mouse thigh infection model at 73.5 mg/kg, ip administered every 24 hrs by 2-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342691Plasma concentration in New Zealand white rabbit assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 168 hrs by liquid scintillation counting method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID342698Drug level in New Zealand white rabbit bone assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 336 hrs by liquid scintillation counting method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324123AUC/MIC ratio of Streptococcus pneumoniae 1325 infected neutropenic mouse thigh infection model at 1.73 mg/kg, ip administered every 24 hrs by 2-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324132AUC/MBC ratio of methicillin-resistant Staphylococcus aureus infected neutropenic mouse thigh infection model at 53.5 mg/kg, ip administered every 24 hrs by 2-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342917Drug level in New Zealand white rabbit periostium assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 168 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID342960Drug level in New Zealand white rabbit skeletal muscle assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 24 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID510809AUC (0-infinity) in ICR mouse at 5 mg/kg, ip2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
AID324090AUC/MBC ratio of Staphylococcus aureus 31005 infected neutropenic mouse thigh infection model at 67.7 mg/kg, ip administered every 72 hrs by static effect experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324075AUC/MIC ratio of Streptococcus pneumoniae 1293 infected neutropenic mouse thigh infection model at 1.01 mg/kg, ip administered every 72 hrs by static effect experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID285240Antimicrobial activity against erythromycin-resistant Streptococcus pyogenes FB764371 by broth microdilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activity and resistance development profiling of dalbavancin.
AID324116AUC/MBC ratio of Staphylococcus aureus 33591 infected neutropenic mouse thigh infection model at 93 mg/kg, ip administered every 72 hrs by 1-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID1143553Antibacterial activity against vancomycin-resistant VanA phenotype of Enterococcus faecium ATCC 51559 assessed as growth inhibition by broth microdilution method2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Membrane active vancomycin analogues: a strategy to combat bacterial resistance.
AID285241Antimicrobial activity against erythromycin-susceptible Streptococcus pyogenes FB1041775 by broth microdilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activity and resistance development profiling of dalbavancin.
AID324120AUC/MBC ratio of Staphylococcus aureus 31005 infected neutropenic mouse thigh infection model at 94.6 mg/kg, ip administered every 72 hrs by 1-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID548527Antimicrobial activity against Oxacillin-susceptible coagulase-negative Staphylococcus by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.
AID324121AUC/MIC ratio of Streptococcus pneumoniae 1199 infected neutropenic mouse thigh infection model at 0.57 mg/kg, ip administered every 24 hrs by 2-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342688Plasma concentration in New Zealand white rabbit assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 24 hrs by liquid scintillation counting method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324054Bactericidal activity against methicillin-resistant Staphylococcus aureus ATCC 29213 infected neutropenic Swiss ICR mouse thigh infection model assessed as drug level causing 2-log reduction of bacterial count at 15 mg/kg, ip dosed every 36 hrs2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342955Drug level in New Zealand white rabbit bone marrow assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 72 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID342962Drug level in New Zealand white rabbit skeletal muscle assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 120 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID342957Drug level in New Zealand white rabbit bone marrow assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 168 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID510797Antimicrobial activity against Bacillus anthracis str. Ames infected in BALB/c mouse prophylaxis model assessed as mouse survival at 60 mg/kg, ip administered 36 hrs post infection every 36 hrs for 14 days measured after 42 days2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
AID324070AUC/MBC ratio of Staphylococcus aureus 33591 infected neutropenic mouse thigh infection model at 22.3 mg/kg, ip administered every 24 hrs by static effect experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324076AUC/MIC ratio of Streptococcus pneumoniae 1199 infected neutropenic mouse thigh infection model at 0.72 mg/kg, ip administered every 72 hrs by static effect experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324057Bactericidal activity against methicillin-resistant Staphylococcus aureus ATCC 29213 infected neutropenic Swiss ICR mouse thigh infection model assessed as drug level causing 1-log reduction of bacterial count at 10 mg/kg, ip dosed every 72 hrs2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324029Half life in bacterial pathogen-infected neutropenic Swiss ICR mouse thigh infection model at 10 mg/kg, ip2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID285242Antimicrobial activity against erythromycin-susceptible Streptococcus pyogenes FB1041626 by broth microdilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activity and resistance development profiling of dalbavancin.
AID324036AUC in bacterial pathogen-infected neutropenic Swiss ICR mouse thigh infection model at 40 mg/kg, ip2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342932Drug level in New Zealand white rabbit epiphyseal plate assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 24 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324071AUC/MBC ratio of Staphylococcus aureus 31005 infected neutropenic mouse thigh infection model at 49.3 mg/kg, ip administered every 24 hrs by static effect experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324016Antibacterial activity against Streptococcus pneumoniae ATCC 10813 by microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342951Drug level in New Zealand white rabbit meniscus assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 72 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324085AUC/MBC ratio of Staphylococcus aureus ATCC 25923 infected neutropenic mouse thigh infection model at 160 mg/kg, ip administered every 72 hrs by static effect experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324091AUC/MIC ratio of Streptococcus pneumoniae 1199 infected neutropenic mouse thigh infection model at 0.49 mg/kg, ip administered every 24 hrs by 1-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID285231Antimicrobial activity against methicillin-susceptible Staphylococcus aureus FB1050986 by broth microdilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activity and resistance development profiling of dalbavancin.
AID548744Antimicrobial activity against Vancomycin-nonsusceptible Enterococcus faecium assessed as percent susceptible isolate by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.
AID324122AUC/MIC ratio of Streptococcus pneumoniae 1293 infected neutropenic mouse thigh infection model at 0.65 mg/kg, ip administered every 24 hrs by 2-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324152Bactericidal activity in Streptococcus pneumoniae ATCC 10813 infected non-neutropenic mouse thigh infection model assessed as drug level causing 2-log reduction of bacterial count at 2.03 mg/kg/6days2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324105AUC/MIC ratio of Streptococcus pneumoniae 1293 infected neutropenic mouse thigh infection model at 1.28 mg/kg, ip administered every 72 hrs by 1-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342701Drug level in New Zealand white rabbit bone marrow assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 72 hrs by liquid scintillation counting method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID342966Antibacterial activity against Staphylococcus2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324041Antibacterial activity against Staphylococcus aureus ATCC 25923 in presence of 95% mouse serum2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID548533Antimicrobial activity against Beta-hemolytic Streptococcus by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.
AID510807AUC (0-infinity) in ICR mouse at 5 mg/kg, iv2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
AID342699Drug level in New Zealand white rabbit bone marrow assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 12 hrs by liquid scintillation counting method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324074AUC/MIC ratio of Streptococcus pneumoniae 1325 infected neutropenic mouse thigh infection model at 0.83 mg/kg, ip administered every 72 hrs by static effect experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID285238Antimicrobial activity against Staphylococcus haemolyticus FB953975 by broth microdilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activity and resistance development profiling of dalbavancin.
AID324047Bactericidal activity against penicillin-susceptible Streptococcus pneumoniae ATCC 10813 infected neutropenic Swiss ICR mouse thigh infection model assessed as drug level causing 2-log reduction of bacterial count at 2.3 mg/kg, ip dosed every 12 hrs2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324134AUC/MIC ratio of Streptococcus pneumoniae 1325 infected neutropenic mouse thigh infection model at 1.16 mg/kg, ip administered every 72 hrs by 2-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342967Antibacterial activity against Streptococcus2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324020Antibacterial activity against methicillin-resistant Staphylococcus aureus by microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324115AUC/MBC ratio of Staphylococcus aureus ATCC 25923 infected neutropenic mouse thigh infection model at 185 mg/kg, ip administered every 72 hrs by 1-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324118AUC/MBC ratio of Staphylococcus aureus Smith infected neutropenic mouse thigh infection model at 95 mg/kg, ip administered every 72 hrs by 1-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342687Plasma concentration in New Zealand white rabbit assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 12 hrs by liquid scintillation counting method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID285235Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis FB758988 by broth microdilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activity and resistance development profiling of dalbavancin.
AID324037Cmax in bacterial pathogen-infected neutropenic Swiss ICR mouse thigh infection model at 40 mg/kg, ip2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324050Bactericidal activity against methicillin-resistant Staphylococcus aureus ATCC 29213 infected neutropenic Swiss ICR mouse thigh infection model assessed as drug level causing 1-log reduction of bacterial count at 267 mg/kg, ip dosed every 24 hrs2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342709Drug level in New Zealand white rabbit nucleus pulposus assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 168 hrs by liquid scintillation counting method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID285237Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis FB896283 by broth microdilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activity and resistance development profiling of dalbavancin.
AID548743Antimicrobial activity against Vancomycin-susceptible Enterococcus faecium assessed as percent susceptible isolate by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.
AID510959fCmax in ICR mouse at 20 mg/kg, ip after 2 hrs2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
AID510804T>MIC in ICR mouse at 5 mg/kg, ip2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
AID324143AUC/MIC ratio of Staphylococcus aureus 307109 infected neutropenic mouse thigh infection model at 37 mg/kg, ip administered every 72 hrs by 2-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324018Antibacterial activity against Staphylococcus aureus 33591 by microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342705Drug level in New Zealand white rabbit nucleus pulposus assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 12 hrs by liquid scintillation counting method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID510956Ratio of fCmax in ICR mouse at 20 mg/kg, ip single dose after 2 hrs to MIC for Bacillus anthracis Ames2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
AID285236Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis FB750345 by broth microdilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activity and resistance development profiling of dalbavancin.
AID324044Bactericidal activity in ip dosed penicillin-susceptible Streptococcus pneumoniae ATCC 10813 infected neutropenic mouse thigh infection model assessed as reduction of colony count after 48 hrs by time kill study2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID510953Antimicrobial activity against Bacillus anthracis str. Ames after 18-24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
AID285253Bacterial killing activity of Streptococcus pyogenes at >=1 ug/ml2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activity and resistance development profiling of dalbavancin.
AID324042Antibacterial activity against Staphylococcus aureus ATCC 25923 in presence of 95% mouse serum ultrafiltrate2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324067AUC/MIC ratio of methicillin-resistant Staphylococcus aureus infected neutropenic mouse thigh infection model at 37.7 mg/kg, ip administered every 24 hrs by static effect experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID285252Bacterial killing activity of Streptococcus pyogenes at 0.25 ug/ml2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activity and resistance development profiling of dalbavancin.
AID324144AUC/MIC ratio of Staphylococcus aureus 31005 infected neutropenic mouse thigh infection model at 127 mg/kg, ip administered every 72 hrs by 2-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID510961fAUC in ICR mouse at 20 mg/kg, ip2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
AID342920Drug level in New Zealand white rabbit articular cartilage assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 24 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324096AUC/MIC ratio of Staphylococcus aureus ATCC 25923 infected neutropenic mouse thigh infection model at 51.2 mg/kg, ip administered every 24 hrs by 1-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324149AUC/MBC ratio of Staphylococcus aureus 307109 infected neutropenic mouse thigh infection model at 37 mg/kg, ip administered every 72 hrs by 2-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID548737Antimicrobial activity against Oxacillin-susceptible Staphylococcus aureus assessed as percent susceptible isolate by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.
AID342689Plasma concentration in New Zealand white rabbit assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 72 hrs by liquid scintillation counting method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID342961Drug level in New Zealand white rabbit skeletal muscle assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 72 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID510954AUC in patient with skin and soft tissue infections at 1000 mg, iv after 7 days2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
AID324102AUC/MBC ratio of methicillin-resistant Staphylococcus aureus infected neutropenic mouse thigh infection model at 45.3 mg/kg, ip administered every 24 hrs by 1-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342934Drug level in New Zealand white rabbit epiphyseal plate assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 120 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID342947Drug level in New Zealand white rabbit synovial space assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 168 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324100AUC/MBC ratio of Staphylococcus aureus ATCC 25923 infected neutropenic mouse thigh infection model at 51.2 mg/kg, ip administered every 24 hrs by 1-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324153Bactericidal activity in Streptococcus pneumoniae ATCC 10813 infected neutropenic mouse thigh infection model assessed as drug level causing 1-log reduction of bacterial count at 4.13 mg/kg/6days2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324035Half life in bacterial pathogen-infected neutropenic Swiss ICR mouse thigh infection model at 40 mg/kg, ip2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324110AUC/MIC ratio of Staphylococcus aureus 33591 infected neutropenic mouse thigh infection model at 93 mg/kg, ip administered every 72 hrs by 1-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324077AUC/MIC ratio of Streptococcus pneumoniae 1396 infected neutropenic mouse thigh infection model at 0.52 mg/kg, ip administered every 72 hrs by static effect experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID285246Antimicrobial activity against vancomycin-susceptible Enterococcus faecalis FB7671912007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activity and resistance development profiling of dalbavancin.
AID342936Drug level in New Zealand white rabbit epiphyseal plate assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 336 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324150AUC/MBC ratio of Staphylococcus aureus 31005 infected neutropenic mouse thigh infection model at 127 mg/kg, ip administered every 72 hrs by 2-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342923Drug level in New Zealand white rabbit articular cartilage assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 168 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID342921Drug level in New Zealand white rabbit articular cartilage assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 72 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324156Antibacterial activity against methicillin-resistant Staphylococcus aureus in presence of 95% mouse serum ultrafiltrate2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324068AUC/MIC ratio of Staphylococcus aureus Smith infected neutropenic mouse thigh infection model at 33.5 mg/kg, ip administered every 24 hrs by static effect experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324130AUC/MBC ratio of Staphylococcus aureus ATCC 25923 infected neutropenic mouse thigh infection model at 60 mg/kg, ip administered every 24 hrs by 2-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324039AUC in bacterial pathogen-infected neutropenic Swiss ICR mouse thigh infection model at 40 mg/kg, ip2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324154Bactericidal activity in Streptococcus pneumoniae ATCC 10813 infected neutropenic mouse thigh infection model assessed as drug level causing 2-log reduction of bacterial count at 4.13 mg/kg/6days2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342946Drug level in New Zealand white rabbit synovial space assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 120 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324058Bactericidal activity against methicillin-resistant Staphylococcus aureus ATCC 29213 infected neutropenic Swiss ICR mouse thigh infection model assessed as drug level causing 2-log reduction of bacterial count at 10 mg/kg, ip dosed every 72 hrs2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324032Half life in bacterial pathogen-infected neutropenic Swiss ICR mouse thigh infection model at 20 mg/kg, ip2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342914Drug level in New Zealand white rabbit periostium assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 24 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID285243Antimicrobial activity against vancomycin-susceptible Enterococcus faecalis FB7663232007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activity and resistance development profiling of dalbavancin.
AID324046Bactericidal activity against penicillin-susceptible Streptococcus pneumoniae ATCC 10813 infected neutropenic Swiss ICR mouse thigh infection model assessed as drug level causing 1-log reduction of bacterial count at 2.3 mg/kg, ip dosed every 12 hrs2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID510808Plasma concentration in ICR mouse at 20 mg/kg, ip after 6 days2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
AID206645Antibacterial activity against Methicillin resistant staphylococcus aureus (MRSA)2003Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23
Semi-synthetic glycopeptide antibacterials.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID324111AUC/MIC ratio of methicillin-resistant Staphylococcus aureus infected neutropenic mouse thigh infection model at 62 mg/kg, ip administered every 72 hrs by 1-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324059AUC/MIC ratio of Streptococcus pneumoniae 1199 infected neutropenic mouse thigh infection model at 0.40 mg/kg, ip administered every 24 hrs by static effect experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324125AUC/MIC ratio of Streptococcus pneumoniae ATCC 10813 infected neutropenic mouse thigh infection model at 1.75 mg/kg, ip administered every 24 hrs by 2-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342931Drug level in New Zealand white rabbit epiphyseal plate assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 12 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324024AUC in bacterial pathogen-infected neutropenic Swiss ICR mouse thigh infection model at 2.5 mg/kg, ip2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324078AUC/MIC ratio of Streptococcus pneumoniae ATCC 10813 infected neutropenic mouse thigh infection model at 0.71 mg/kg, ip administered every 72 hrs by static effect experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342927Drug level in New Zealand white rabbit compact bone assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 72 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID285248Bacterial killing activity of methicillin-resistant Staphylococcus aureus at 0.25 ug/ml2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activity and resistance development profiling of dalbavancin.
AID324040Cmax in bacterial pathogen-infected neutropenic Swiss ICR mouse thigh infection model at 40 mg/kg, ip2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342959Drug level in New Zealand white rabbit skeletal muscle assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 12 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324056Bactericidal activity against penicillin-susceptible Streptococcus pneumoniae ATCC 10813 infected neutropenic Swiss ICR mouse thigh infection model assessed as drug level causing 2-log reduction of bacterial count at 0.71 mg/kg, ip dosed every 72 hrs2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342706Drug level in New Zealand white rabbit nucleus pulposus assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 24 hrs by liquid scintillation counting method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324045Bactericidal activity in ip dosed methicillin-resistant Staphylococcus aureus ATCC 29213 infected neutropenic mouse thigh infection model assessed as reduction of colony count after 96 hrs by time kill study2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324126AUC/MIC ratio of Staphylococcus aureus ATCC 25923 infected neutropenic mouse thigh infection model at 60 mg/kg, ip administered every 24 hrs by 2-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342715Drug level in New Zealand white rabbit blood assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 72 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324033AUC in bacterial pathogen-infected neutropenic Swiss ICR mouse thigh infection model at 20 mg/kg, ip2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID510805AUC (0-infinity) in ICR mouse at 20 mg/kg, iv2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
AID324026Half life in bacterial pathogen-infected neutropenic Swiss ICR mouse thigh infection model at 5 mg/kg, ip2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID548742Antimicrobial activity against Vancomycin-nonsusceptible Enterococcus faecalis assessed as percent susceptible isolate by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.
AID324089AUC/MBC ratio of Staphylococcus aureus 307109 infected neutropenic mouse thigh infection model at 31 mg/kg, ip administered every 72 hrs by static effect experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324119AUC/MBC ratio of Staphylococcus aureus 307109 infected neutropenic mouse thigh infection model at 34 mg/kg, ip administered every 72 hrs by 1-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID548746Antimicrobial activity against viridans group Streptococcus assessed as percent susceptible isolate by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.
AID342912Drug level in New Zealand white rabbit blood assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 336 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID342950Drug level in New Zealand white rabbit meniscus assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 24 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324139AUC/MIC ratio of Staphylococcus aureus ATCC 25923 infected neutropenic mouse thigh infection model at 214 mg/kg, ip administered every 72 hrs by 2-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342954Drug level in New Zealand white rabbit bone marrow assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 24 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID510795Antimicrobial activity against Bacillus anthracis str. Ames infected in BALB/c mouse prophylaxis model assessed as mouse survival at 120 mg/kg, ip administered 36 hrs post infection every 72 hrs for 14 days measured after 42 days2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
AID342918Drug level in New Zealand white rabbit periostium assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 336 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324140AUC/MIC ratio of Staphylococcus aureus 33591 infected neutropenic mouse thigh infection model at 114 mg/kg, ip administered every 72 hrs by 2-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324099AUC/MIC ratio of Staphylococcus aureus Smith infected neutropenic mouse thigh infection model at 50.7 mg/kg, ip administered every 24 hrs by 1-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324136AUC/MIC ratio of Streptococcus pneumoniae 1199 infected neutropenic mouse thigh infection model at 0.99 mg/kg, ip administered every 72 hrs by 2-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID510950Half life in ICR mouse at 5 mg/kg, ip2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
AID207007Antibacterial activity against Vancomycin resistant staphylococcus aureus (VRSA); NA=data not available2003Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23
Semi-synthetic glycopeptide antibacterials.
AID324053Bactericidal activity against methicillin-resistant Staphylococcus aureus ATCC 29213 infected neutropenic Swiss ICR mouse thigh infection model assessed as drug level causing 1-log reduction of bacterial count at 15 mg/kg, ip dosed every 36 hrs2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342933Drug level in New Zealand white rabbit epiphyseal plate assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 72 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID510802T>MIC in ICR mouse at 20 mg/kg, ip2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
AID324092AUC/MIC ratio of Streptococcus pneumoniae 1293 infected neutropenic mouse thigh infection model at 0.55 mg/kg, ip administered every 24 hrs by 1-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324082AUC/MIC ratio of Staphylococcus aureus Smith infected neutropenic mouse thigh infection model at 59 mg/kg, ip administered every 72 hrs by static effect experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342700Drug level in New Zealand white rabbit bone marrow assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 24 hrs by liquid scintillation counting method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324063AUC/MIC ratio of Streptococcus pneumoniae ATCC 10813 infected neutropenic mouse thigh infection model at 1.34 mg/kg, ip administered every 24 hrs by static effect experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342690Plasma concentration in New Zealand white rabbit assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 120 hrs by liquid scintillation counting method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324148AUC/MBC ratio of Staphylococcus aureus Smith infected neutropenic mouse thigh infection model at 148 mg/kg, ip administered every 72 hrs by 2-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID510794Antimicrobial activity against Bacillus anthracis str. Ames infected in BALB/c mouse prophylaxis model assessed as mouse survival at 120 mg/kg, ip administered 48 hrs post infection every 72 hrs for 14 days measured after 42 days2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
AID342943Drug level in New Zealand white rabbit synovial space assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 12 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID342697Drug level in New Zealand white rabbit bone assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 168 hrs by liquid scintillation counting method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID342703Drug level in New Zealand white rabbit bone marrow assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 168 hrs by liquid scintillation counting method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID342949Drug level in New Zealand white rabbit meniscus assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 12 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID342922Drug level in New Zealand white rabbit articular cartilage assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 120 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID342940Drug level in New Zealand white rabbit ligament assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 120 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID548739Antimicrobial activity against Oxacillin-susceptible coagulase-negative Staphylococcus assessed as percent susceptible isolate by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.
AID510796Antimicrobial activity against Bacillus anthracis str. Ames infected in BALB/c mouse prophylaxis model assessed as mouse survival at 60 mg/kg, ip administered 48 hrs post infection every 36 hrs for 14 days measured after 42 days2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
AID510799Antimicrobial activity against Bacillus anthracis str. Ames infected in BALB/c mouse prophylaxis model assessed as mouse survival at >=30 mg/kg, ip administered 24 hrs post infection every 36 hrs for 14 days measured after 42 days2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
AID342953Drug level in New Zealand white rabbit bone marrow assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 12 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID510811Cmax in ICR mouse at 20 mg/kg, ip after 2 hrs2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
AID342948Drug level in New Zealand white rabbit synovial space assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 336 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324142AUC/MIC ratio of Staphylococcus aureus Smith infected neutropenic mouse thigh infection model at 148 mg/kg, ip administered every 72 hrs by 2-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342711Drug level in New Zealand white rabbit blood assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 24 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324060AUC/MIC ratio of Streptococcus pneumoniae 1293 infected neutropenic mouse thigh infection model at 0.44 mg/kg, ip administered every 24 hrs by static effect experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342925Drug level in New Zealand white rabbit compact bone assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 12 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324049Bactericidal activity against penicillin-susceptible Streptococcus pneumoniae ATCC 10813 infected neutropenic Swiss ICR mouse thigh infection model assessed as drug level causing 2-log reduction of bacterial count at 1.34 mg/kg, ip dosed every 24 hrs2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342935Drug level in New Zealand white rabbit epiphyseal plate assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 168 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324084AUC/MIC ratio of Staphylococcus aureus 31005 infected neutropenic mouse thigh infection model at 67.7 mg/kg, ip administered every 72 hrs by static effect experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID1143549Antibacterial activity against methicillin-sensitive Staphylococcus aureus MTCC 737 assessed as growth inhibition by broth microdilution method2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Membrane active vancomycin analogues: a strategy to combat bacterial resistance.
AID342911Drug level in New Zealand white rabbit blood assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 168 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324031Cmax in bacterial pathogen-infected neutropenic Swiss ICR mouse thigh infection model at 10 mg/kg, ip2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324073AUC/MBC ratio of Staphylococcus aureus Smith infected neutropenic mouse thigh infection model at 33.5 mg/kg, ip administered every 24 hrs by static effect experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID1143552Antibacterial activity against vancomycin-sensitive Enterococcus faecium ATCC 19634 assessed as growth inhibition by broth microdilution method2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Membrane active vancomycin analogues: a strategy to combat bacterial resistance.
AID324104AUC/MIC ratio of Streptococcus pneumoniae 1325 infected neutropenic mouse thigh infection model at 0.99 mg/kg, ip administered every 72 hrs by 1-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342945Drug level in New Zealand white rabbit synovial space assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 72 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID1143550Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as growth inhibition by broth microdilution method2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Membrane active vancomycin analogues: a strategy to combat bacterial resistance.
AID324079AUC/MIC ratio of Staphylococcus aureus ATCC 25923 infected neutropenic mouse thigh infection model at 160 mg/kg, ip administered every 72 hrs by static effect experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324051Bactericidal activity against penicillin-susceptible Streptococcus pneumoniae ATCC 10813 infected neutropenic Swiss ICR mouse thigh infection model assessed as drug level causing 1-log reduction of bacterial count at 1.26 mg/kg, ip dosed every 36 hrs2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342928Drug level in New Zealand white rabbit compact bone assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 120 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID342924Drug level in New Zealand white rabbit articular cartilage assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 336 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID342938Drug level in New Zealand white rabbit ligament assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 24 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324129AUC/MIC ratio of Staphylococcus aureus Smith infected neutropenic mouse thigh infection model at 73.5 mg/kg, ip administered every 24 hrs by 2-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID510952Antimicrobial activity against Bacillus anthracis str. Ames infected in BALB/c mouse assessed as mouse survival at 30 mg/kg, ip bid administered 48 hrs post infection for 14 days measured after 42 days2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
AID342702Drug level in New Zealand white rabbit bone marrow assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 120 hrs by liquid scintillation counting method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324141AUC/MIC ratio of methicillin-resistant Staphylococcus aureus infected neutropenic mouse thigh infection model at 85 mg/kg, ip administered every 72 hrs by 2-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342956Drug level in New Zealand white rabbit bone marrow assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 120 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324137AUC/MIC ratio of Streptococcus pneumoniae 1396 infected neutropenic mouse thigh infection model at 1.69 mg/kg, ip administered every 72 hrs by 2-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324155Antibacterial activity against methicillin-resistant Staphylococcus aureus in presence of 95% mouse serum2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324028Cmax in bacterial pathogen-infected neutropenic Swiss ICR mouse thigh infection model at 5 mg/kg, ip2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID510810Half life in ICR mouse at 20 mg/kg, ip2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
AID324066AUC/MIC ratio of Staphylococcus aureus 31005 infected neutropenic mouse thigh infection model at 49.3 mg/kg, ip administered every 24 hrs by static effect experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324151Bactericidal activity in Streptococcus pneumoniae ATCC 10813 infected non-neutropenic mouse thigh infection model assessed as drug level causing 1-log reduction of bacterial count at 2.03 mg/kg/6days2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324069AUC/MBC ratio of Staphylococcus aureus ATCC 25923 infected neutropenic mouse thigh infection model at 42.7 mg/kg, ip administered every 24 hrs by static effect experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID342939Drug level in New Zealand white rabbit ligament assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 72 hrs by autoradioluminography2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
AID324101AUC/MBC ratio of Staphylococcus aureus 33591 infected neutropenic mouse thigh infection model at 27.7 mg/kg, ip administered every 24 hrs by 1-log killing experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID510958fCmax in ICR mouse at 5 mg/kg, ip after 2 hrs2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
AID324055Bactericidal activity against penicillin-susceptible Streptococcus pneumoniae ATCC 10813 infected neutropenic Swiss ICR mouse thigh infection model assessed as drug level causing 1-log reduction of bacterial count at 0.71 mg/kg, ip dosed every 72 hrs2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID324064AUC/MIC ratio of Staphylococcus aureus ATCC 25923 infected neutropenic mouse thigh infection model at 42.7 mg/kg, ip administered every 24 hrs by static effect experiment2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
AID208624Antibacterial activity against Streptococcus pneumoniae2003Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23
Semi-synthetic glycopeptide antibacterials.
AID342694Drug level in New Zealand white rabbit bone assessed as [14C]dalbavancin level per gram of tissue at 20 mg/kg, iv after 24 hrs by liquid scintillation counting method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (75.00)29.6817
2010's2 (25.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 67.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index67.22 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.26 (4.65)
Search Engine Demand Index109.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (67.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (30)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Open-label, Pilot Clinical Trial of Dalbavancin for the Treatment of Susceptible Gram-positive Infections Requiring Prolonged Intravenous Antibiotic Therapy [NCT03982030]Phase 40 participants (Actual)Interventional2023-04-30Withdrawn(stopped due to Lack of funding)
Evaluation of Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients [NCT02940730]Phase 410 participants (Actual)Interventional2017-05-01Completed
Phase 2, Open-Label, Randomized, Multicenter Study to Compare the Efficacy and Safety of Dalbavancin to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Documented Infective Endocarditis [NCT03148756]Phase 22 participants (Actual)Interventional2017-05-12Terminated(stopped due to Study stopped due to business reasons.)
A Pragmatic Trial Designed to Evaluate a New Critical Pathway for Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections [NCT02961764]Phase 4313 participants (Actual)Interventional2016-11-29Completed
Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections [NCT03233438]Phase 491 participants (Actual)Interventional2017-07-24Completed
A Phase 2, Multicenter, Open-label, Randomized, Comparator-controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis Known or Suspected to be Due to Gram-positive Organisms [NCT03091439]Phase 21 participants (Actual)Interventional2017-05-15Terminated(stopped due to Business decision outlined by the corporation.)
Comparing Oral Versus Parenteral Antimicrobial Therapy (COPAT) Trial [NCT05977868]Phase 4135 participants (Anticipated)Interventional2023-08-04Enrolling by invitation
A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections [NCT02814916]Phase 3188 participants (Anticipated)Interventional2017-03-31Recruiting
Preliminary Evaluation of Dalbavancin's Efficacy in People Who Use Drugs With Severe Gram-positive Infections [NCT04847921]Phase 2/Phase 311 participants (Actual)Interventional2021-04-30Terminated(stopped due to Delays in recruitment due to COVID-19 and higher than acceptable loss to followup.)
Xydalba Utilization Registry: A Multicenter, Prospective and Retrospective Registry to Characterize the Use of Xydalba [NCT03696901]16 participants (Actual)Observational2018-11-21Terminated(stopped due to Terminated)
A Phase 3, Double-blinded, Randomized, Comparator Trial of the Safety and Efficacy of a Single Dose of Dalbavancin to Twice Daily Linezolid for the Treatment of Community Acquired Bacterial Pneumonia [NCT02269644]Phase 30 participants (Actual)Interventional2015-11-30Withdrawn
Observational Study on the Use of Xydalba: A Multicenter, Prospective Study to Characterize the Use of Xydalba in France [NCT03726216]151 participants (Actual)Observational [Patient Registry]2018-09-06Completed
Dalbavancin For The Treatment Of Gram Positive Osteomyelitis Or Joint Infections Including Prosthetic Hip Or Knee Infections [NCT03426761]Phase 441 participants (Actual)Interventional2018-01-25Completed
Hospital Avoidance Strategies for Treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) [NCT03372941]Phase 411 participants (Actual)Interventional2019-03-04Terminated(stopped due to Funding and recruitment limited by pandemic)
A Phase 2, Single-center, Open-label, Randomized, Comparator-controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis Known or Suspected to be Due to Gram-Positive Organisms [NCT02685033]Phase 280 participants (Actual)Interventional2016-03-15Completed
Efficacy of Dalbavancin in Osteoarticular Infections Associated With Hip and Knee Replacements [NCT05046860]43 participants (Anticipated)Interventional2021-09-29Not yet recruiting
Dalbavancin as an Option for Treatment of S. Aureus Bacteremia (DOTS): A Phase 2b, Multicenter, Randomized, Open-Label, Assessor-Blinded Superiority Study to Compare the Efficacy and Safety of Dalbavancin to Standard of Care Antibiotic Therapy for the Com [NCT04775953]Phase 2200 participants (Actual)Interventional2021-04-22Active, not recruiting
Evaluation of the Efficacy and Safety of Suppressive Therapy With DALBAVANCINE in Device Infections [NCT06089044]15 participants (Actual)Observational2020-01-01Completed
Pharmacokinetics of a Single-Dose of Dalbavancin in Preterm Neonates to Infants Ages 3 Months With Suspected or Confirmed Bacterial Infection [NCT02688790]Phase 18 participants (Actual)Interventional2016-04-01Terminated
A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety and Tolerability Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections [NCT01946568]Phase 136 participants (Anticipated)Interventional2013-06-30Completed
A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Dalbavancin In Hospitalized Adolescents, Aged 12 Through 17 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections [NCT00678106]Phase 110 participants (Actual)Interventional2008-09-30Completed
Randomized Open-label Controlled Trial Evaluating a Single-dose Intravenous Dalbavancin Versus Standard Antibiotic Therapy During Catheter-related Bloodstream Infections Due to Staphylococcus Aureus [NCT05117398]Phase 3406 participants (Anticipated)Interventional2023-06-23Recruiting
Phase II, Randomized, Open-Label, Multi-Center Study to Evaluate the Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections With Suspected or Confirmed Gram-Positive Bacterial Pathogens [NCT00057369]Phase 288 participants Interventional2001-02-28Active, not recruiting
A Phase 3b, Double-Blind, Multicenter, Randomized Study to Compare the Efficacy and Safety of Single Dose Dalbavancin to a Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections [NCT02127970]Phase 3698 participants (Actual)Interventional2014-04-18Completed
A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regiment (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections [NCT01339091]Phase 3573 participants (Actual)Interventional2011-03-31Completed
A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regimen (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections [NCT01431339]Phase 3739 participants (Actual)Interventional2011-07-31Completed
Retrospective Observational Study on Dalbavancin Real-life Utilization in Diabetic Patients Suffering From Infections - DALBADIA Study [NCT04959799]98 participants (Actual)Observational2022-01-02Completed
Retrospective Effectiveness Study of Dalbavancin and Other Standard of Care of the Same Class (i.v. Lipo and Glyco-peptides) in Patients With ABSSSI [NCT04298463]184 participants (Actual)Observational2020-06-18Completed
A Phase 3, Multicenter, Double-Blind, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis of the Long Bones Known or Suspected to be Due to [NCT02344511]Phase 30 participants (Actual)Interventional2016-03-31Withdrawn
Evaluation of Intravenous Dalbavancin for Treatment of Peritonitis in Peritoneal Dialysis Patients [NCT04624451]10 participants (Anticipated)Observational2020-06-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01339091 (4) [back to overview]>= 20% Reduction in Lesion Area
NCT01339091 (4) [back to overview]Clinical Status
NCT01339091 (4) [back to overview]Clinical Status
NCT01339091 (4) [back to overview]Early Clinical Efficacy
NCT01431339 (4) [back to overview]Early Clinical Efficacy
NCT01431339 (4) [back to overview]>= 20% Reduction in Lesion Area
NCT01431339 (4) [back to overview]Clinical Status
NCT01431339 (4) [back to overview]Clinical Status
NCT02127970 (9) [back to overview]Percentage of Participants by Resource Utilization Categories
NCT02127970 (9) [back to overview]Percentage of Participants With Complete Resolution of Local Signs of Infection
NCT02127970 (9) [back to overview]Percentage of Participants by Skin and Soft Tissue Infection-Convenience (SSTI-C) Questionnaire: Overall Satisfaction Response
NCT02127970 (9) [back to overview]Percentage of Participants by Investigator Assessment of Clinical Outcome
NCT02127970 (9) [back to overview]Percentage of Participants by Clinical Status Based on Localized Fluctuance and Heat/Warmth at End of Treatment (EOT)
NCT02127970 (9) [back to overview]Percentage of Participants by Clinical Status at End of Treatment (EOT) and Final Visit (FV)
NCT02127970 (9) [back to overview]Percentage of Participants Achieving Clinical Outcome of Success Based on Key Target Pathogen at Baseline
NCT02127970 (9) [back to overview]Change From Baseline in Participant's Assessment of Pain
NCT02127970 (9) [back to overview]Percentage of Participants Who Were Clinical Responders 48-72 Hours After the Initiation of Study Drug
NCT02685033 (13) [back to overview]Percentage of Participants With Clinical Response at Day 365 in the mITT Population
NCT02685033 (13) [back to overview]Percentage of Participants With Clinical Improvement at Day 21 in the mITT Population
NCT02685033 (13) [back to overview]Percentage of Participants With Clinical Improvement at Day 21 in the CE Population
NCT02685033 (13) [back to overview]Number of Participants With Clinical Cure by Baseline Pathogen at Day 42 in the CE Population
NCT02685033 (13) [back to overview]Number of Participants With Clinical Cure by Baseline Pathogen at Day 180 in the CE Population
NCT02685033 (13) [back to overview]Number of Participants With Clinical Cure by Baseline Pathogen at Day 180 in the CE Population
NCT02685033 (13) [back to overview]Number of Participants With Clinical Cure by Baseline Pathogen at Day 42 in the CE Population
NCT02685033 (13) [back to overview]Percentage of Participants With Clinical Response at Day 42 in the mITT Population
NCT02685033 (13) [back to overview]Percentage of Participants With Clinical Response at Day 42 in the Microbiological Modified Intent-to-Treat (Micro-mITT) Population
NCT02685033 (13) [back to overview]Percentage of Participants With Clinical Response at Day 42 in the Clinically Evaluable (CE) Population
NCT02685033 (13) [back to overview]Percentage of Participants With Clinical Response at Day 365 in the CE Population
NCT02685033 (13) [back to overview]Percentage of Participants With Clinical Response at Day 180 in the CE Population
NCT02685033 (13) [back to overview]Percentage of Participant With Clinical Response at Day 180 in the mITT Population
NCT02940730 (5) [back to overview]Determine Dalbavancin Peritoneal Fluid Clearance in Peritoneal Dialysis Patients After Intravenous and Intraperitoneal Administration
NCT02940730 (5) [back to overview]Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug, Graded According to NCI CTCAE Version 3.0
NCT02940730 (5) [back to overview]Determine Dalbavancin Plasma Clearance in Peritoneal Dialysis Patients After Intravenous and Intraperitoneal Administration
NCT02940730 (5) [back to overview]Determine Dalbavancin Plasma Area Under the Curve in Peritoneal Dialysis Patients After Intravenous and Intraperitoneal Administration
NCT02940730 (5) [back to overview]Determine Dalbavancin Peritoneal Fluid Area Under the Curve in Peritoneal Dialysis Patients After Intravenous and Intraperitoneal Administration
NCT02961764 (19) [back to overview]Patient Satisfaction With Care: Factors Contributing to Dissatisfaction With Receiving IV
NCT02961764 (19) [back to overview]Patient Satisfaction With Care: Factors Contributing to Preference for Outpatient Care
NCT02961764 (19) [back to overview]Patient Satisfaction With Care: Factors Contributing to Satisfaction With Receiving IV
NCT02961764 (19) [back to overview]Patient Satisfaction With Care: Factors for Dissatisfaction With Your Hospital Stay
NCT02961764 (19) [back to overview]Patient Work and Productivity Loss as Assessed Through the Work Productivity and Activity Impairment Questionnaire
NCT02961764 (19) [back to overview]Use of a Peripherally-Inserted Central Catheter (PICC) Line or Central Line to Administer Antibiotic Therapy
NCT02961764 (19) [back to overview]Number of Participants With Infection-related Emergency Department (ED) Visits
NCT02961764 (19) [back to overview]Number of Infection-related Total Admitted Hospital Days
NCT02961764 (19) [back to overview]Number of Participants With All Cause Hospitalizations in the 30 Days Post Discharge From the Hospital or Release From the ED
NCT02961764 (19) [back to overview]Number of Participants With Infection-related Outpatient Healthcare Visits
NCT02961764 (19) [back to overview]Number of Participants With Serious Adverse Events (SAEs)
NCT02961764 (19) [back to overview]Number of Total Admitted Hospital Days
NCT02961764 (19) [back to overview]Patient Satisfaction With Care: Satisfaction With Hospital Stay
NCT02961764 (19) [back to overview]Patient Satisfaction With Care: Satisfaction With Receiving IV Antibiotic Therapy
NCT02961764 (19) [back to overview]Patient Satisfaction With Care: Satisfaction With the Average Time to Administer Each IV
NCT02961764 (19) [back to overview]Patient Satisfaction With Care: Satisfied With the Number of IV Infusions Received Per Day
NCT02961764 (19) [back to overview]Patient Satisfaction With Care: Wait in Emergency Room
NCT02961764 (19) [back to overview]Total Length of Stay in Emergency Department (ED) During the Initial Episode of Care
NCT02961764 (19) [back to overview]Patient Health-related Quality of Life (HRQoL) Assessed by the Short Form 12 (SF-12) 12-Item Patient Questionnaire
NCT03091439 (2) [back to overview]Number of Participants With Clinical Improvement at Day 28 in the CE Population
NCT03091439 (2) [back to overview]Number of Participants With Clinical Improvement at Day 28 in the Modified Intent-to-Treat (mITT) Population
NCT03148756 (13) [back to overview]Percentage of Participants With Clinical Outcome of Success by Pathogen at Day 42 in the ITT Population
NCT03148756 (13) [back to overview]Number of Participants With Clinical Response at Day 84 in the Intent-to Treat (ITT) Population
NCT03148756 (13) [back to overview]Percentage of Participants With Microbiological Success by Pathogen at Day 84 in the ITT Population
NCT03148756 (13) [back to overview]Percentage of Participants With Microbiological Success by Pathogen at Day 84 in the CE Population
NCT03148756 (13) [back to overview]Percentage of Participants With Microbiological Success by Pathogen at Day 42 in the ITT Population
NCT03148756 (13) [back to overview]Percentage of Participants With Microbiological Success by Pathogen at Day 42 in the CE Population
NCT03148756 (13) [back to overview]Percentage of Participants With Clinical Outcome of Success by Pathogen at Day 84 in the ITT Population
NCT03148756 (13) [back to overview]Percentage of Participants With Clinical Outcome of Success by Pathogen at Day 84 in the CE Population
NCT03148756 (13) [back to overview]Percentage of Participants With Clinical Outcome of Success by Pathogen at Day 42 in the CE Population
NCT03148756 (13) [back to overview]Percentage of Participants With Clinical Outcome of Success at Day 84 in the CE Population
NCT03148756 (13) [back to overview]Percentage of Participants With Clinical Outcome of Success at Day 42 in the ITT Population
NCT03148756 (13) [back to overview]Percentage of Participants With Clinical Outcome of Success at Day 42 in the Clinically Evaluable (CE) Population
NCT03148756 (13) [back to overview]Number of Participants With Day 84 Mortality in the Safety Population
NCT03233438 (14) [back to overview]Number of Participants With Serious Adverse Events (SAEs)
NCT03233438 (14) [back to overview]Number of Infection-related Total Admitted Hospital Days
NCT03233438 (14) [back to overview]Healthcare Costs
NCT03233438 (14) [back to overview]Patient Satisfaction With Care: Satisfaction With Receiving IV Antibiotic Therapy
NCT03233438 (14) [back to overview]Patient Satisfaction With Care: Satisfaction With the Average Time to Administer Each IV
NCT03233438 (14) [back to overview]Patient Satisfaction With Care: Satisfied With the Number of IV Infusions Received Per Day
NCT03233438 (14) [back to overview]Patient Satisfaction With Care: Wait in Emergency Room
NCT03233438 (14) [back to overview]Patient Health-related Quality of Life (HRQoL) Assessed by the Short Form 12 (SF-12) 12-Item Patient Questionnaire
NCT03233438 (14) [back to overview]Patient Satisfaction With Care: Factors Contributing to Dissatisfaction With Receiving IV
NCT03233438 (14) [back to overview]Patient Satisfaction With Care: Factors Contributing to Satisfaction With Receiving IV
NCT03233438 (14) [back to overview]Patient Satisfaction With Care: Factors for Dissatisfaction With Your Hospital Stay
NCT03233438 (14) [back to overview]Patient Work and Productivity Loss as Assessed Through the Work Productivity and Activity Impairment Questionnaire
NCT03233438 (14) [back to overview]Patient Satisfaction With Care: Satisfaction With Hospital Stay
NCT03233438 (14) [back to overview]Number of Total Admitted Hospital Days

>= 20% Reduction in Lesion Area

Clinical response at 48-72 hours post study drug initiation, based on measurements of acute bacterial skin and skin structure infections (ABSSSI) lesion size (NCT01339091)
Timeframe: 48-72 hours after the initiation of study therapy

,
Interventionparticipants (Number)
Clinical ResponderClinical Non-Responder
Dalbavancin25929
Vancomycin +/- Oral Linezolid25926

[back to top]

Clinical Status

Compare the clinical efficacy at end of treatment visit of dalbavancin to the comparator regimen based on lesion size, local signs, temperature and receipt of non-study antibiotics (NCT01339091)
Timeframe: End of Treatment Visit (Day 14-15)

,
Interventionparticipants (Number)
Clinical SuccessClinical Failure
Dalbavancin21432
Vancomycin +/- Oral Linezolid22221

[back to top]

Clinical Status

Compare the clinical efficacy at the day 28 follow-up visit of dalbavancin to the comparator regimen based on lesion size, local signs, temperature and receipt of non-study antibiotics (NCT01339091)
Timeframe: Follow-Up Visit (day 28)

,
Interventionparticipants (Number)
Clinical SuccessClinical Failure
Dalbavancin21214
Vancomycin +/- Oral Linezolid2209

[back to top]

Early Clinical Efficacy

Clinical response at 48-72 hours post study drug initiation, based on measurements of acute bacterial skin and skin structure infections (ABSSSI) lesion size and temperature (NCT01339091)
Timeframe: 48-72 hours after the initiation of study therapy

,
Interventionparticipants (Number)
Clinical ResponderClinical Non-Responder
Dalbavancin24048
Vancomycin +/- Oral Linezolid23352

[back to top]

Early Clinical Efficacy

Clinical response at 48-72 hours post study drug initiation, based on measurements of acute bacterial skin and skin structure infections (ABSSSI) lesion size and temperature (NCT01431339)
Timeframe: After 48-72 hours of therapy

,
Interventionparticipants (Number)
Clinical ResponderClinical Non-Responder
Dalbavancin28586
Vancomycin With Possible Switch to Oral Linezolid28880

[back to top]

>= 20% Reduction in Lesion Area

Clinical response at 48-72 hours post study drug initiation, based on measurements of acute bacterial skin and skin structure infections (ABSSSI) lesion size (NCT01431339)
Timeframe: 48-72 hours after the initiation of study therapy

,
Interventionparticipants (Number)
Clinical ResponderClinical Non-Responder
Dalbavancin32546
Vancomycin With Possible Switch to Oral Linezolid31652

[back to top]

Clinical Status

Compare the clinical efficacy at end of treatment visit of dalbavancin to the comparator regimen based on lesion size, local signs, temperature and receipt of other therapy (NCT01431339)
Timeframe: End of Treatment Visit (Day 14-15)

,
Interventionparticipants (Number)
Clinical SucccessClinical Failure
Dalbavancin30321
Vancomycin With Possible Switch to Oral Linezolid28022

[back to top]

Clinical Status

Compare the clinical efficacy at the short term follow-up visit of dalbavancin to the comparator regimen based on lesion size, local signs temperature and receipt of other therapy (NCT01431339)
Timeframe: Follow-Up Visit (day 28)

,
Interventionparticipants (Number)
Clinical SuccessClinical Failure
Dalbavancin28311
Vancomycin With Possible Switch to Oral Linezolid25715

[back to top]

Percentage of Participants by Resource Utilization Categories

Resource Utilization Categories included: Any additional visits (including urgent care), Any additional procedures, Any additional tests, Any home visits or nursing care and Any ER Visits. The percentage of participants in each category is reported. (NCT02127970)
Timeframe: Final Visit (Day 28 +/- 2 days)

,
Interventionpercentage of participants (Number)
Any Additional Visits (including Urgent Care)Any Additional ProceduresAny Additional TestsAny Home Visits or Home Nursing CareAny ER Visits
Single-Dose Dalbavancin1.21.51.91.50.3
Two-Dose Dalbavancin0.61.62.81.20.9

[back to top]

Percentage of Participants With Complete Resolution of Local Signs of Infection

Resolution of Local Signs of Infection that include absence of purulence/drainage, erythema, heat/localized warmth, pain/tenderness to palpation, fluctuance, and swelling/induration. (NCT02127970)
Timeframe: Day 3-4, Day 8, EOT (Day 14-15) and Final Visit (Day 28 +/- 2 days)

,
Interventionpercentage of participants (Number)
Day 3-4Day 8EOT VisitFinal Visit
Single-Dose Dalbavancin1.922.356.385.8
Two-Dose Dalbavancin1.521.156.289.8

[back to top]

Percentage of Participants by Skin and Soft Tissue Infection-Convenience (SSTI-C) Questionnaire: Overall Satisfaction Response

"The SSTI-C Questionnaire is an 11-item self-reported questionnaire that measures subjective experiences of the participant. One of the items assessed was overall satisfaction with treatment. Participants answered the question: Overall, how satisfied were you with your antibiotic treatment? using one of the following responses: Extremely satisfied, Moderately satisfied, Not at all satisfied, Slightly satisfied and Very satisfied. The percentage of participants in each category is reported." (NCT02127970)
Timeframe: EOT (Day 14-15)

,
Interventionpercentage of participants (Number)
Extremely SatisfiedModerately SatisfiedNot at all SatisfiedSlightly SatisfiedVery Satisfied
Single-Dose Dalbavancin53.69.50.90.335.8
Two-Dose Dalbavancin56.97.20.90.933.7

[back to top]

Percentage of Participants by Investigator Assessment of Clinical Outcome

A successful outcome was based on resolution or improvement of all signs and symptoms of the infection to such an extent that no further antibacterial treatment was given. An unsuccessful outcome was the opposite of successful. An Indeterminate outcome was defined as any of the data needed to determine a successful or unsuccessful outcome were missing. (NCT02127970)
Timeframe: Day 3-4, Day 8, EOT (Day 14-15) and Final Visit (Day 28 +/- 2 days)

,
Interventionpercentage of participants (Number)
Successful Outcome (Day 3-4)Unsuccessful Outcome (Day 3-4)Indeterminate (Day 3-4)Successful Outcome (Day 8)Unsuccessful Outcome (Day 8)Indeterminate (Day 8)Successful Outcome (EOT)Unsuccessful Outcome (EOT)Indeterminate (EOT)Successful Outcome (Final Visit)Unsuccessful Outcome (Final Visit)Indeterminate (Final Visit)
Single-Dose Dalbavancin93.40.36.392.20.67.292.52.94.690.22.67.2
Two-Dose Dalbavancin93.00.96.193.30.36.492.71.55.891.01.77.3

[back to top]

Percentage of Participants by Clinical Status Based on Localized Fluctuance and Heat/Warmth at End of Treatment (EOT)

Clinical Success was defined as localized fluctuance and heat/warmth that if present at Baseline must be improved and no worse than mild. Clinical Failure was defined as the opposite to success. Clinical status was Indeterminate if any of the data needed to determine clinical success or clinical failure were missing. (NCT02127970)
Timeframe: EOT (Day 14-15)

,
Interventionpercentage of participants (Number)
Clinical SuccessClinical FailureIndeterminate
Single-Dose Dalbavancin84.87.77.4
Two-Dose Dalbavancin85.46.97.7

[back to top]

Percentage of Participants by Clinical Status at End of Treatment (EOT) and Final Visit (FV)

Clinical Success is defined as follows: For evaluation at EOT visit, lesion area must be decreased by ≥80% from baseline and at FV lesion area must be decreased by ≥90% from baseline; Temperature is ≤37.6°C; Local signs of tenderness to palpation and swelling/induration are no worse than mild; For evaluation at EOT visit, local signs of fluctuance and localized heat/warmth must be improved from baseline and no worse than mild, and at FV local signs of fluctuance and localized heat/warmth must be absent; for participants with a wound infection the severity of purulent drainage is improved and no worse than mild relative to baseline. Clinical Failure is defined as the opposite to success or if the participant died during the study period up to visit or received study therapy for ABSSSI beyond the protocol treatment period. Clinical status is Indeterminate if any of the data needed to determine clinical success or clinical failure were missing. (NCT02127970)
Timeframe: End of Treatment (Day 14-15 after the initiation of study drug) and Final Visit (28 ±2 days after the initiation of study drug)

,
Interventionpercentage of participants (Number)
EOT; Clinical SuccessEOT; Clinical FailureEOT; IndeterminateFV; Clinical SuccessFV; Clinical FailureFV; Indeterminate
Single-Dose Dalbavancin84.012.04.084.58.07.4
Two-Dose Dalbavancin84.810.34.985.17.27.3

[back to top]

Percentage of Participants Achieving Clinical Outcome of Success Based on Key Target Pathogen at Baseline

A successful outcome was based on resolution or improvement of all signs and symptoms of the infection to such an extent that no further antibacterial treatment was given. (NCT02127970)
Timeframe: Day 3-4 and EOT (Day 14-15)

,
Interventionpercentage of participants (Number)
Staphylococcus aureus (Day 3-4)Streptococcus agalactiae (Day 3-4)Streptococcus anginosus group (Day 3-4)Streptococcus dysgalactiae (Day 3-4)Streptococcus pyogenes (Day 3-4)Enterococcus faecalis (Day 3-4)Staphylococcus aureus (EOT)Streptococcus agalactiae (EOT)Streptococcus anginosus group (EOT)Streptococcus dysgalactiae (EOT)Streptococcus pyogenes (EOT)Enterococcus faecalis (EOT)
Single-Dose Dalbavancin88.5100.093.9100.0100.0100.087.883.381.8100.092.9100.0
Two-Dose Dalbavancin85.366.7100.0100.081.880.091.783.389.5100.081.8100.0

[back to top]

Change From Baseline in Participant's Assessment of Pain

"Using the Brief Pain Inventory Scale, participants rated their pain right now on a scale where: 0=no pain to 10=pain as bad as you can imagine. A negative change from Baseline indicated improvement." (NCT02127970)
Timeframe: Baseline (Day 0) to Day 3-4, Day 8, EOT (Day 14-15) and Final Visit (Day 28 + /- 2 days)

,
InterventionScores on a scale (Mean)
BaselineChange from Baseline to Day 3-4Change from Baseline to Day 8Change from Baseline to EOT VisitChange from Baseline to Final Visit
Single-Dose Dalbavancin7.7-3.9-5.9-6.9-7.5
Two-Dose Dalbavancin7.8-3.8-5.8-6.9-7.4

[back to top]

Percentage of Participants Who Were Clinical Responders 48-72 Hours After the Initiation of Study Drug

Clinical responder was defined as a participant who was alive and had received no rescue therapy for acute bacterial skin and skin structure infection (ABSSSI) prior to the 48-72 hour infection site assessment (if an antibiotic has been given for another reason, the participant will not be considered a non-responder for this reason); and examination of the participant's ABSSSI lesion demonstrates a decrease of ≥ 20% in lesion area (calculated as the longest length multiplied by the longest perpendicular width) relative to the baseline measurement. (NCT02127970)
Timeframe: Up to 48-72 hours after the initiation of study drug

Interventionpercentage of participants (Number)
Single-Dose Dalbavancin81.4
Two-Dose Dalbavancin84.2

[back to top]

Percentage of Participants With Clinical Response at Day 365 in the mITT Population

Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring >6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit). (NCT02685033)
Timeframe: Day 365

,
Interventionpercentage of participants (Number)
Clinical CureClinical FailureIndeterminate
Dalbavancin94.03.03.0
Standard of Care87.5012.5

[back to top]

Percentage of Participants With Clinical Improvement at Day 21 in the mITT Population

Clinical improvement was defined as no worsening of pain from baseline, if present (subjective pain and/or point tenderness), and improvement in inflammation (as measured by C-reactive protein [CRP]). (NCT02685033)
Timeframe: Baseline to Day 21

Interventionpercentage of participants (Number)
Dalbavancin94.0
Standard of Care62.5

[back to top]

Percentage of Participants With Clinical Improvement at Day 21 in the CE Population

Clinical improvement was defined as no worsening of pain from baseline, if present (subjective pain and/or point tenderness), and improvement in inflammation (as measured by C-reactive protein [CRP]). (NCT02685033)
Timeframe: Baseline to Day 21

Interventionpercentage of participants (Number)
Dalbavancin94.0
Standard of Care62.5

[back to top]

Number of Participants With Clinical Cure by Baseline Pathogen at Day 42 in the CE Population

Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring >6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit). (NCT02685033)
Timeframe: Day 42

Interventionparticipants (Number)
Staphylococcus aureusStaphylococcus epidermidisEnterococcus faecalisStreptococcus agalactiaeCorynebacterium striatumKlebsiella pneumoniaePseudomonas aeruginosaProteus mirabilisRaoultella planticolaSerratia marcescens
Standard of Care5211110100

[back to top]

Number of Participants With Clinical Cure by Baseline Pathogen at Day 180 in the CE Population

Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring >6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit). (NCT02685033)
Timeframe: Day 180

Interventionparticipants (Number)
Staphylococcus aureusStaphylococcus epidermidisStaphylococcus haemolyticusStaphylococcus pasteuriStaphylococcus hominisStaphylococcus simulansEnterococcus faecalisEnterococcus faeciumStreptococcus agalactiaeStreptococcus dysgalactiaeStreptococcus pyogenesCorynebacterium striatumAerococcus viridansGlobicatella speciesMicrococcus luteusPeptoniphilus hareiAnaerococcus prevotiiFinegoldia magnaPeptostrep. anaerobiusEscherichia coliKlebsiella pneumoniaePseudomonas aeruginosaEnterobacter cloacae complexMorganella morganiiProteus mirabilisRaoultella planticolaEscherichia hermanniiPluralibacter gergoviaeAcinetobacter calcoaceticusBacteroides fragilisBacteroides thetaiotaomicronBacteroides vulgatusPorphyromonas asaccharolyticaPrevotella melaninogenicaPrevotella disiensPrevotella intermediaPrevotella species
Dalbavancin39631117111121112111322221111121122111

[back to top]

Number of Participants With Clinical Cure by Baseline Pathogen at Day 180 in the CE Population

Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring >6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit). (NCT02685033)
Timeframe: Day 180

Interventionparticipants (Number)
Staphylococcus aureusStaphylococcus epidermidisEnterococcus faecalisStreptococcus agalactiaeCorynebacterium striatumKlebsiella pneumoniaePseudomonas aeruginosaProteus mirabilisRaoultella planticolaSerratia marcescens
Standard of Care5201111111

[back to top]

Number of Participants With Clinical Cure by Baseline Pathogen at Day 42 in the CE Population

Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring >6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit). (NCT02685033)
Timeframe: Day 42

Interventionparticipants (Number)
Staphylococcus aureusStaphylococcus epidermidisStaphylococcus haemolyticusStaphylococcus pasteuriStaphylococcus hominisStaphylococcus simulansEnterococcus faecalisEnterococcus faeciumStreptococcus agalactiaeStreptococcus dysgalactiaeStreptococcus pyogenesCorynebacterium striatumAerococcus viridansGlobicatella speciesMicrococcus luteusPeptoniphilus hareiAnaerococcus prevotiiFinegoldia magnaPeptostrep. anaerobiusEscherichia coliKlebsiella pneumoniaePseudomonas aeruginosaEnterobacter cloacae complexMorganella morganiiProteus mirabilisRaoultella planticolaEscherichia hermanniiPluralibacter gergoviaeAcinetobacter calcoaceticusBacteroides fragilisBacteroides thetaiotaomicronBacteroides vulgatusPorphyromonas asaccharolyticaPrevotella melaninogenicaPrevotella disiensPrevotella intermediaPrevotella species
Dalbavancin41631117111121112111322221111121122111

[back to top]

Percentage of Participants With Clinical Response at Day 42 in the mITT Population

Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring >6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit). (NCT02685033)
Timeframe: Day 42

,
Interventionpercentage of participants (Number)
Clinical CureClinical FailureIndeterminate
Dalbavancin97.00.03.0
Standard of Care87.512.50.0

[back to top]

Percentage of Participants With Clinical Response at Day 42 in the Microbiological Modified Intent-to-Treat (Micro-mITT) Population

Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring >6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit). (NCT02685033)
Timeframe: Day 42

,
Interventionpercentage of participants (Number)
Clinical CureClinical FailureIndeterminate
Dalbavancin96.80.03.2
Standard of Care87.512.50.0

[back to top]

Percentage of Participants With Clinical Response at Day 42 in the Clinically Evaluable (CE) Population

Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring >6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit). (NCT02685033)
Timeframe: Day 42

,
Interventionpercentage of participants (Number)
Clinical CureClinical FailureIndeterminate
Dalbavancin97.00.03.0
Standard of Care87.512.50.0

[back to top]

Percentage of Participants With Clinical Response at Day 365 in the CE Population

Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring >6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit). (NCT02685033)
Timeframe: Day 365

,
Interventionpercentage of participants (Number)
Clinical CureClinical FailureIndeterminate
Dalbavancin95.51.53.0
Standard of Care87.5012.5

[back to top]

Percentage of Participants With Clinical Response at Day 180 in the CE Population

Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring >6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit). (NCT02685033)
Timeframe: Day 180

,
Interventionpercentage of participants (Number)
Clinical CureClinical FailureIndeterminate
Dalbavancin95.51.53.0
Standard of Care87.50.012.5

[back to top]

Percentage of Participant With Clinical Response at Day 180 in the mITT Population

Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring >6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit). (NCT02685033)
Timeframe: Day 180

,
Interventionpercentage of participants (Number)
Clinical CureClinical FailureIndeterminate
Dalbavancin94.03.03.0
Standard of Care87.50.012.5

[back to top]

Determine Dalbavancin Peritoneal Fluid Clearance in Peritoneal Dialysis Patients After Intravenous and Intraperitoneal Administration

Dalbavancin peritoneal fluid clearance (NCT02940730)
Timeframe: 14 days

InterventionL/h (Mean)
Dalbavancin Via IV0.586
Dalbavancin Via IP0.034

[back to top] [back to top]

Determine Dalbavancin Plasma Clearance in Peritoneal Dialysis Patients After Intravenous and Intraperitoneal Administration

Dalbavancin plasma clearance (NCT02940730)
Timeframe: 14 days

InterventionL/h (Mean)
Dalbavancin Via IV0.0298
Dalbavancin Via IP0.059

[back to top]

Determine Dalbavancin Plasma Area Under the Curve in Peritoneal Dialysis Patients After Intravenous and Intraperitoneal Administration

14 day plasma concentrations (NCT02940730)
Timeframe: 14 days

Interventionmg*h/L (Mean)
Dalbavancin Via IV40573.2
Dalbavancin Via IP13532.3

[back to top]

Determine Dalbavancin Peritoneal Fluid Area Under the Curve in Peritoneal Dialysis Patients After Intravenous and Intraperitoneal Administration

14 day peritoneal fluid concentrations (NCT02940730)
Timeframe: 14 days

Interventionmg*h/L (Mean)
Dalbavancin Via IV2125
Dalbavancin Via IP69654.3

[back to top]

Patient Satisfaction With Care: Factors Contributing to Dissatisfaction With Receiving IV

Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported). (NCT02961764)
Timeframe: 14 Days

,
InterventionParticipants (Number)
Got in the way of work/schoolGot in way of performing daily normal activitiesGot in the way of providing care to othersIV antibiotic therapy was expensiveRequired me to make appointmentsAdministered at healthcare setting w/limited hoursRequired traveling to and from appointmentsRequired to wait to be seen by providerIV antibiotic therapy took too long to administerRequired having a PICC or central line insertedCaused an IV site infectionIV antibiotic therapy made me feel worseNot adequately monitored by healthcare providersNot administered by skilled healthcare providersIV antibiotic therapy made me feel concernedRequired a nurse/healthcare worker coming to homeRequired administration to self/caregiver at homeOtherNot dissatisfied w/receiving IV antibiotic therapy
New Critical Pathway141000023202002001105
Usual Care23101101120211200472

[back to top]

Patient Satisfaction With Care: Factors Contributing to Preference for Outpatient Care

Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported). (NCT02961764)
Timeframe: 14 Days

,
InterventionParticipants (Number)
To avoid hospital stay for 1 or more nightsTo allow me to return to work/schoolTo return to performing daily normal livingTo allow me to return to providing care to othersOutpatient care would be more affordableOutpatient care would be more convenientTo ensure monitoring by healthcare providersAdministered by skilled healthcare providersOtherI would not prefer outpatient care
New Critical Pathway9144653638642227114
Usual Care5237482721431017338

[back to top]

Patient Satisfaction With Care: Factors Contributing to Satisfaction With Receiving IV

Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported). (NCT02961764)
Timeframe: Day 14

,
InterventionParticipants (Number)
Allowed me to return to work/schoolAllowed me to return to daily normal activitiesAllowed me to return to providing care to othersIV antibiotic therapy was affordableAdministered at appointments that I could scheduleAdministered quickly once arrived at apptAdministered at setting that had convenient hoursEnsured regular monitoring by healthcare providersAdministered by skilled healthcare providersIV antibiotic therapy made me feel betterAllowed to receive care for skin infection at homeConvenient to administer by self/caregiver at homeOtherNot satisfied with receiving IV antibiotic therapy
New Critical Pathway5081524511171629588010483
Usual Care374838294432651554249

[back to top]

Patient Satisfaction With Care: Factors for Dissatisfaction With Your Hospital Stay

Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported). (NCT02961764)
Timeframe: Day 14

,
InterventionParticipant (Number)
Hospital stay interfered with work/schoolStay got in way of daily normal activitiesStay got in the way of providing care to othersHospital stay was expensiveDid not provide adequate monitoring by providersDid not provide well trained healthcare providersHospital stay made me feel worseHospital stay made me feel concernedHospital stay was uncomfortableHospital stay disrupted my sleepOtherI was not dissatisfied with my hospital stay
New Critical Pathway81086100756212
Usual Care111182333141112733

[back to top]

Patient Work and Productivity Loss as Assessed Through the Work Productivity and Activity Impairment Questionnaire

Number of days with lost/reduced productivity during follow-up, as measured with Work Productivity and Activity Impairment (WPAI) Questionnaire (NCT02961764)
Timeframe: Day 14

,
InterventionPercentage (Mean)
AbsenteeismImpairment while workingOverall work impairmentActivity impairment
New Critical Pathway18.910.816.415.9
Usual Care17.414.521.324.2

[back to top]

Use of a Peripherally-Inserted Central Catheter (PICC) Line or Central Line to Administer Antibiotic Therapy

(NCT02961764)
Timeframe: 44 Days

,
InterventionParticipants (Number)
Peripheral IVCentral linePICC lineNo Line
New Critical Pathway14101136
Usual Care9301143

[back to top] [back to top] [back to top]

Number of Participants With All Cause Hospitalizations in the 30 Days Post Discharge From the Hospital or Release From the ED

(NCT02961764)
Timeframe: Follow-up: 30 Days

InterventionParticipants (Number)
Usual Care7
New Critical Pathway12

[back to top] [back to top]

Number of Participants With Serious Adverse Events (SAEs)

(NCT02961764)
Timeframe: 44 Days

InterventionParticipants (Count of Participants)
Usual Care11
New Critical Pathway16

[back to top]

Number of Total Admitted Hospital Days

Number of days during the initial hospitalization (for those initially hospitalized) and all other hospitalizations (NCT02961764)
Timeframe: 44 Days

InterventionDays (Mean)
Usual Care2.3
New Critical Pathway1.2

[back to top]

Patient Satisfaction With Care: Satisfaction With Hospital Stay

Patients rated their satisfaction on a 10-point scale, where 0 was the worst experience possible and 10 the best experience possible. (NCT02961764)
Timeframe: Day 14

InterventionScores on a Scale (Mean)
Usual Care8.2
New Critical Pathway8.0

[back to top]

Patient Satisfaction With Care: Satisfaction With Receiving IV Antibiotic Therapy

Patients rated their satisfaction on a 10-point scale, where 0 was the worst experience possible and 10 the best experience possible. (NCT02961764)
Timeframe: Day 14

InterventionScores on a Scale (Mean)
Usual Care8.7
New Critical Pathway9.0

[back to top]

Patient Satisfaction With Care: Satisfaction With the Average Time to Administer Each IV

Patients rated their satisfaction on a 10-point scale, where 0 was the worst experience possible and 10 the best experience possible. (NCT02961764)
Timeframe: Day 14

InterventionScores on a Scale (Mean)
Usual Care8.6
New Critical Pathway8.8

[back to top]

Patient Satisfaction With Care: Satisfied With the Number of IV Infusions Received Per Day

Patients rated their satisfaction on a 10-point scale, where 0 was the worst experience possible and 10 the best experience possible. (NCT02961764)
Timeframe: Day 14

InterventionScores on a scale (Mean)
Usual Care8.4
New Critical Pathway9.0

[back to top]

Patient Satisfaction With Care: Wait in Emergency Room

Patients rated their satisfaction on a 10-point scale, where 0 was the worst experience possible and 10 the best experience possible. (NCT02961764)
Timeframe: Day 14

Interventionscores on a scale (Mean)
Usual Care7.8
New Critical Pathway8.3

[back to top]

Total Length of Stay in Emergency Department (ED) During the Initial Episode of Care

Time spent in ED in hours from triage to release (either admitted to the hospital, admitted to observation, or released to home) (NCT02961764)
Timeframe: Initial Care: 14 Days

InterventionHours (Mean)
Usual Care7.7
New Critical Pathway6.1

[back to top] [back to top]

Number of Participants With Clinical Improvement at Day 28 in the CE Population

Clinical improvement was based on an assessment of pain and/or point tenderness compared to Baseline and assessment of inflammation as measured by C-reactive Protein (CRP). Clinical improvement was defined as no worsening of pain from Baseline, if present, and improvement in inflammation. (NCT03091439)
Timeframe: Baseline (Day 0) to Day 28

InterventionParticipants (Count of Participants)
Dalbavancin1
Standard of Care0

[back to top]

Number of Participants With Clinical Improvement at Day 28 in the Modified Intent-to-Treat (mITT) Population

Clinical improvement was based on an assessment of pain and/or point tenderness compared to Baseline and assessment of inflammation as measured by C-reactive Protein (CRP). Clinical improvement was defined as no worsening of pain from Baseline, if present, and improvement in inflammation. (NCT03091439)
Timeframe: Baseline (Day 0) to Day 28

InterventionParticipants (Count of Participants)
Dalbavancin1

[back to top]

Percentage of Participants With Clinical Outcome of Success by Pathogen at Day 42 in the ITT Population

Clinical outcome was either success or failure. Success was defined as resolution of clinical signs and symptoms of complicated bacteremia or infective endocarditis (IE) such that no additional antibiotic therapy was required. (NCT03148756)
Timeframe: Day 42

Interventionpercentage of participants (Number)
Standard of Care100

[back to top]

Number of Participants With Clinical Response at Day 84 in the Intent-to Treat (ITT) Population

Clinical response was either success or failure. Success was defined as resolution of clinical signs and symptoms of complicated bacteremia or infective endocarditis (IE) such that no additional antibiotic therapy was required. Failure was defined as: ongoing signs and symptoms considered by the investigator to be related to complicated bacteremia or IE requiring additional antibacterial therapy or unplanned valve replacement, recurrent bacteremia, death during the study period up to Day 84 or discontinuation of the study medication due to an adverse event. (NCT03148756)
Timeframe: Day 84

InterventionParticipants (Count of Participants)
SuccessFailure
Standard of Care10

[back to top]

Percentage of Participants With Microbiological Success by Pathogen at Day 84 in the ITT Population

Microbiological outcome could be either microbiologic success or microbiologic failure. Microbiologic Success was defined as no further growth of baseline pathogen from blood cultures. (NCT03148756)
Timeframe: Day 84

Interventionpercentage of participants (Number)
Standard of Care100

[back to top]

Percentage of Participants With Microbiological Success by Pathogen at Day 84 in the CE Population

Microbiological outcome could be either microbiologic success or microbiologic failure. Microbiologic Success was defined as no further growth of baseline pathogen from blood cultures. (NCT03148756)
Timeframe: Day 84

Interventionpercentage of participants (Number)
Standard of Care100

[back to top]

Percentage of Participants With Microbiological Success by Pathogen at Day 42 in the ITT Population

Microbiological outcome could be either microbiologic success or microbiologic failure. Microbiologic Success was defined as no further growth of baseline pathogen from blood cultures. (NCT03148756)
Timeframe: Day 42

Interventionpercentage of participants (Number)
Standard of Care100

[back to top]

Percentage of Participants With Microbiological Success by Pathogen at Day 42 in the CE Population

Microbiological outcome could be either microbiologic success or microbiologic failure. Microbiologic Success was defined as no further growth of baseline pathogen from blood cultures. (NCT03148756)
Timeframe: Day 42

Interventionpercentage of participants (Number)
Standard of Care100

[back to top]

Percentage of Participants With Clinical Outcome of Success by Pathogen at Day 84 in the ITT Population

Clinical outcome was either success or failure. Success was defined as resolution of clinical signs and symptoms of complicated bacteremia or infective endocarditis (IE) such that no additional antibiotic therapy was required. (NCT03148756)
Timeframe: Day 84

Interventionpercentage of participants (Number)
Standard of Care100

[back to top]

Percentage of Participants With Clinical Outcome of Success by Pathogen at Day 84 in the CE Population

Clinical outcome was either success or failure. Success was defined as resolution of clinical signs and symptoms of complicated bacteremia or infective endocarditis (IE) such that no additional antibiotic therapy was required. (NCT03148756)
Timeframe: Day 84

Interventionpercentage of participants (Number)
Standard of Care100

[back to top]

Percentage of Participants With Clinical Outcome of Success by Pathogen at Day 42 in the CE Population

Clinical outcome was either success or failure. Success was defined as resolution of clinical signs and symptoms of complicated bacteremia or infective endocarditis (IE) such that no additional antibiotic therapy was required. (NCT03148756)
Timeframe: Day 42

Interventionpercentage of participants (Number)
Standard of Care100

[back to top]

Percentage of Participants With Clinical Outcome of Success at Day 84 in the CE Population

Clinical outcome was either success or failure/relapse. Success was defined as resolution of clinical signs and symptoms of complicated bacteremia or infective endocarditis (IE) such that no additional antibiotic therapy was required. (NCT03148756)
Timeframe: Day 84

Interventionpercentage of participants (Number)
Standard of Care100

[back to top]

Percentage of Participants With Clinical Outcome of Success at Day 42 in the ITT Population

Clinical outcome was either success or failure. Success was defined as resolution of clinical signs and symptoms of complicated bacteremia or infective endocarditis (IE) such that no additional antibiotic therapy was required. (NCT03148756)
Timeframe: Day 42

Interventionpercentage of participants (Number)
Standard of Care100

[back to top]

Percentage of Participants With Clinical Outcome of Success at Day 42 in the Clinically Evaluable (CE) Population

Clinical outcome was either success or failure. Success was defined as resolution of clinical signs and symptoms of complicated bacteremia or infective endocarditis (IE) such that no additional antibiotic therapy was required. (NCT03148756)
Timeframe: Day 42

Interventionpercentage of participants (Number)
Standard of Care100

[back to top]

Number of Participants With Day 84 Mortality in the Safety Population

Day 84 mortality was measured by the number of deaths up to Day 84. (NCT03148756)
Timeframe: Day 84

InterventionParticipants (Count of Participants)
Standard of Care0

[back to top]

Number of Participants With Serious Adverse Events (SAEs)

(NCT03233438)
Timeframe: 44 Days

InterventionParticipants (Count of Participants)
Usual Care1
New Critical Pathway3

[back to top] [back to top]

Healthcare Costs

Cost of hospital inpatient stays, ED visits, healthcare visits, procedures, and biological tests (NCT03233438)
Timeframe: 44 Days

InterventionUSD (Mean)
Usual Care13772.9
New Critical Pathway9421.6

[back to top]

Patient Satisfaction With Care: Satisfaction With Receiving IV Antibiotic Therapy

Patients rated their satisfaction on a 10-point scale, where 0 was the worst experience possible and 10 the best experience possible. (NCT03233438)
Timeframe: 14 Days

Interventionscores on a scale (Mean)
Usual Care7.1
New Critical Pathway8.1

[back to top]

Patient Satisfaction With Care: Satisfaction With the Average Time to Administer Each IV

Patients rated their satisfaction on a 10-point scale, where 0 was the worst experience possible and 10 the best experience possible. (NCT03233438)
Timeframe: 14 Days

Interventionscores on a scale (Mean)
Usual Care7.5
New Critical Pathway8.9

[back to top]

Patient Satisfaction With Care: Satisfied With the Number of IV Infusions Received Per Day

Patients rated their satisfaction on a 10-point scale, where 0 was the worst experience possible and 10 the best experience possible. (NCT03233438)
Timeframe: 14 Days

Interventionscores on a scale (Mean)
Usual Care7.3
New Critical Pathway8.7

[back to top]

Patient Satisfaction With Care: Wait in Emergency Room

Patients rated their satisfaction on a 10-point scale, where 0 was the worst experience possible and 10 the best experience possible. (NCT03233438)
Timeframe: 14 Days

Interventionscores on a scale (Mean)
Usual Care5.1
New Critical Pathway6.9

[back to top] [back to top]

Patient Satisfaction With Care: Factors Contributing to Dissatisfaction With Receiving IV

Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported). (NCT03233438)
Timeframe: 14 Days

,
InterventionParticipants (Number)
Got in the way of work/schoolGot in way of performing daily normal activitiesGot in the way of providing care to othersIV antibiotic therapy was expensiveRequired me to make appointmentsAdministered at healthcare setting w/limited hoursRequired traveling to and from appointmentsRequired to wait to be seen by providerIV antibiotic therapy took too long to administerAdministered too frequentlyRequired having a PICC or central line insertedCaused an IV site infectionIV antibiotic therapy made me feel worseNot adequately monitored by healthcare providersNot administered by skilled healthcare providersIV antibiotic therapy made me feel concernedRequired a nurse/healthcare worker coming to homeRequired administration to self/caregiver at homeOtherNot dissatisfied w/receiving IV antibiotic therapy
New Critical Pathway331000151120300311022
Usual Care111152000044711030700119

[back to top]

Patient Satisfaction With Care: Factors Contributing to Satisfaction With Receiving IV

Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported). (NCT03233438)
Timeframe: 14 Days

,
InterventionParticipants (Number)
Allowed me to return to work/schoolAllowed me to return to daily normal activitiesAllowed me to return to providing care to othersIV antibiotic therapy was affordableAdministered at appointments that I could scheduleAdministered quickly once arrived at apptAdministered at setting that had convenient hoursEnsured regular monitoring by healthcare providersAdministered by skilled healthcare providersIV antibiotic therapy made me feel betterAllowed to receive care for skin infection at homeConvenient to administer by self/caregiver at homeOtherNot satisfied with receiving IV antibiotic therapy
New Critical Pathway15201141371018169012
Usual Care1415862232224197433

[back to top]

Patient Satisfaction With Care: Factors for Dissatisfaction With Your Hospital Stay

Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported). (NCT03233438)
Timeframe: 14 Days

,
InterventionParticipants (Number)
Hospital stay interfered with work/schoolStay got in way of daily normal activitiesStay got in the way of providing care to othersHospital stay was expensiveDid not provide adequate monitoring by providersDid not provide well trained healthcare providersHospital stay made me feel worseHospital stay made me feel concernedHospital stay was uncomfortableHospital stay disrupted my sleepOtherI was not dissatisfied with my hospital stay
New Critical Pathway68544117710612
Usual Care1317107434111224512

[back to top]

Patient Work and Productivity Loss as Assessed Through the Work Productivity and Activity Impairment Questionnaire

(NCT03233438)
Timeframe: Day 10-14

,
InterventionPercentage (Mean)
AbsenteeismImpairment while workingOverall work impairmentActivity impairment
New Critical Pathway36.78.918.018.5
Usual Care49.947.959.360.2

[back to top]

Patient Satisfaction With Care: Satisfaction With Hospital Stay

Patients rated their satisfaction on a 10-point scale, where 0 was the worst experience possible and 10 the best experience possible. (NCT03233438)
Timeframe: 14 Days

Interventionscores on a scale (Mean)
Usual Care7.4
New Critical Pathway7.4

[back to top]

Number of Total Admitted Hospital Days

(NCT03233438)
Timeframe: 44 Days

InterventionDays (Mean)
Usual Care4.9
New Critical Pathway3.2

[back to top]